contribute to atherogenesis is supported by the results of several epidemiologic studies, which suggest that Helicobacter pylori [5] , cytomegalovirus (CMV) [6] , herpes simplex virus (HSV) [7] , and Chlamydia pneumoniae [8] may have atherogenic effects. However, existing epidemiologic data about the association of some of these pathogens with atherosclerosis are conflicting [9] . Moreover, recently published data [10] support the hypothesis that atherosclerosis has an immunopathological component; these data render it improbable that a single infectious agent should assume particular importance in the initiation or progression of atherogenesis.
Our data for 218 consecutive patients (119 men and 99 women; mean age, 64.6 years [range, 29-83 years]) who underwent coronary angiography support the hypothesis of Witkin et al. [1] , that "triggers" such as IL-1RA gene polymorphisms or additional exposure to other pathogens could influence the effect of infectious agents on the development of CAD. Blood samples obtained from all subjects were tested for serologic markers of 6 infectious pathogens (C. pneumoniae, hepatitis A virus, H. pylori, CMV, and influenza virus types A and B). We examined the possible association between seropositivity for a particular microbial agent and angiographically proven coronary artery disease (defined as у1 coronary artery with stenosis 150%-diameter).
Analysis of serologic markers for all 6 microbial agents demonstrated that seropositivity for a single pathogen was not a predictor of risk for CAD. In contrast, the number of infectious pathogens to which individuals have been exposed (i.e., the "infectious burden") correlated with the prevalence of CAD. A total of 48.8% of patients with CAD and 31.2% of patients without CAD tested positive for у4 of the 6 serologic markers ( ); 21.3% of P p .02 patients with CAD and 9% of patients without CAD tested positive for 5 of the 6 serologic markers ( ). Therefore, P p .03 our data support the hypothesis of Witkin et al. [1] that some "triggers" such as cytokine-receptor gene polymorphisms or additional exposure to other pathogens could influence a patient's susceptibility to the atherogenic effect of infection with a particular pathogen.
Candidemia in the Surgical Intensive Care Unit
Sir-We read with great interest the article by Blumberg et al. [1] that reported the results of a multicenter US study of fungemia in the surgical intensive care unit (ICU), in which risk factors and outcomes for 42 candidemic patients were analyzed. In our opinion, there were at least 2 surprising and interesting results: (1) the absence of colonization as a predictor of invasive infection and (2) the protective role of previous antifungal therapy (prophylaxis). We retrospectively analyzed data from 75 cases of fungemia that were seen in 4 surgical ICUs of university hospitals in Slovak Republic in 1992-2002. Only 47 (64%) of 75 episodes were caused by Candida albicans, in contrast to the results of the study by Blumberg et al. [1] , in which fewer than one-half of strains tested in vitro were identified as C. albicans (16 of 35 strains). The second most common strain was C. glabrata, followed by C. tropicalis. In our study, C. glabrata was responsible for only 6.7% cases of fungemia, which underlines the differences in the etiology of fungemia in patients with and without cancer between Europe and the United States [2, 3] . Similarly, a history of colonization with Candida was not a predictor of fungemia in our group (only 3.3% of fungemic patients in the surgical ICU were colonized).
With regard to the use of prior antifungal therapy or prophylaxis, 16.7% of our patients had received fluconazole or amphotericin B 3-5 days before the onset of fungemia. However, we did not observe a statistically significant difference in mortality between patients who received prior treatment and those who did not (14.7% vs. 20%), despite the trend (as was observed in Blumberg's group [1] ) toward lower mortality among patients with prior receipt of antifungals.
Finally, we would like to know the overall and attributable mortality among patients from whom data were analyzed in this valuable study. In our cohort of 75 у10 cfu/mL 6 0 fungemic patients in the surgical ICU, 54.7% died. This is an extremely high mortality rate, although it is quite difficult to distinguish the degree to which candidemia contributed to mortality. Most patients had severe underlying disease, and fungemia is often accompanied by bacteremia, which also contributes to mortality. Therefore, the use of both strategies-prophylaxis and early preventive therapy-for high-risk patients is of emerging importance for prospective trials involving patients in the surgical ICU. 
